Quetiapine Dosing for Bipolar Disorder
For acute mania in adults, start quetiapine at 100 mg/day and rapidly escalate by 100 mg daily to reach 400 mg/day by Day 4, then adjust to a target dose of 600 mg/day (range 400-800 mg/day) by Day 5-6. For bipolar depression, use 300 mg once daily at bedtime, which can be maintained without further titration 1, 2, 3.
Acute Manic Episodes
The evidence strongly supports rapid dose escalation for acute mania:
- Day 1: 100 mg/day
- Day 2: 200 mg/day
- Day 3: 300 mg/day
- Day 4: 400 mg/day
- Day 5: 600 mg/day
- Day 6 onward: Flexible dosing 400-800 mg/day (target 600 mg/day)
This rapid titration schedule achieves significant symptom improvement by Day 4-7 and is generally well tolerated 1, 4. The mean effective dose among responders is approximately 575-600 mg/day, with most patients responding within the 400-800 mg/day range 1. In clinical trials, 92% of patients reached 400 mg/day by Day 4 following this protocol 1.
Critical caveat: Low doses of quetiapine (<400 mg/day) may paradoxically worsen or induce mania due to preferential 5HT2A receptor blockade over D2 antagonism, increasing dopamine concentrations 5. This underscores the importance of rapid escalation to therapeutic doses rather than lingering at subtherapeutic levels.
Bipolar Depression
For depressive episodes, the dosing is simpler and more conservative:
- Day 1: 300 mg once daily at bedtime
- Day 2 onward: Continue 300 mg once daily (can increase to 600 mg if needed, though both doses show comparable efficacy)
The BOLDER I and II trials established that both 300 mg and 600 mg doses are effective for bipolar depression, with no significant difference in efficacy between them 3, 6. The once-daily bedtime dosing leverages quetiapine's sedating properties while treating depression.
Maintenance Therapy
Continue the dose that achieved acute response. For patients stabilized on quetiapine monotherapy, maintain 400-800 mg/day in divided doses (or once-daily for extended-release formulation). The evidence for maintenance therapy is less robust than for acute treatment, but quetiapine is FDA-approved for acute mania in adults 7.
Older Adults (≥55 years)
Use the same dosing schedule as younger adults (400-800 mg/day) but monitor more closely for adverse effects. Post-hoc analysis demonstrates that older adults show comparable efficacy to younger patients with quetiapine 400-800 mg/day for acute mania 8. However, older adults experience higher rates of:
- Postural hypotension (>10% incidence)
- Dizziness
- Somnolence
- Dry mouth
Start with standard dosing but be prepared to adjust based on tolerability. The evidence does not support routinely using lower doses in older adults, as this may lead to undertreatment 8, 9. Monitor orthostatic vital signs, fall risk, and cognitive effects more vigilantly in this population.
Hepatic Impairment
For patients with hepatic impairment, start at 25 mg/day and increase by 25-50 mg/day increments until clinical response is achieved. Quetiapine is extensively hepatically metabolized, requiring substantial dose reduction in liver dysfunction 10. This represents one of the few scenarios where slow titration is appropriate—the alternative of standard dosing risks excessive drug accumulation and toxicity.
Extended-Release Formulation
Quetiapine XR offers once-daily dosing with similar efficacy:
- Day 1: 300 mg once daily
- Day 2: 600 mg once daily
- Day 3 onward: Flexible 400-800 mg once daily
The XR formulation demonstrated significant improvement from Day 4 onward in acute mania trials, with a mean daily dose of 604 mg 2, 11. The once-daily dosing may improve adherence compared to twice-daily immediate-release formulation.
Key Monitoring Points
Watch for metabolic adverse effects (weight gain, hyperglycemia, dyslipidemia), sedation, orthostatic hypotension, and extrapyramidal symptoms. The most common adverse effects are sedation, dry mouth, and somnolence, typically mild to moderate in intensity 2.
Do not use subtherapeutic doses (<400 mg/day for mania) as this increases risk of treatment failure and potential mood destabilization 5. If a patient cannot tolerate therapeutic doses, consider switching to an alternative agent rather than maintaining inadequate dosing.